Anti-Neoplastic Studies Of Standardized Root Extract Of Eurycomal Longifolia (Taf273) Towards Leukaemia by Mohammed, Omar Saeed Ali
ANTI-NEOPLASTIC STUDIES OF STANDARDIZED 
ROOT EXTRACT OF EURYCOMAL LONGIFOLIA 


























ANTI-NEOPLASTIC STUDIES OF STANDARDIZED ROOT 













Thesis submitted in fulfillment of the requirements for the degree of 








UNIVERSITI SAINS MALAYSIA 
 





This thesis is dedicated to … 
 
 
the soul of my parents 
 























First and foremost praise to Allah the almighty who gave me the knowledge, strength 
and the determination to finish my thesis successfully. 
I would like to express my sincerest gratitude to my honourable supervisor, Professor 
Dr Narazah Mohd Yusoff, who has continuously, supported me throughout my study 
with her patience, kindness, motivation and immense knowledge. It would not have 
been possible to write this doctoral thesis without her help and support.  
I also owe my deepest gratitude to my co-supervisors, Professor Chan Kit-Lam, 
Associate Professor Amin Malik Shah Abdul Majid and Associate Professor Dr Wan 
Zaidah Abdullah for their invaluable assistance, support and guidance. 
I am so grateful to Hodeidah Univeristy for giving me the chance and support to 
continue my higher study. 
I am most grateful to Universiti Sains Malaysia (USM) for giving me the chance and 
providing me with all the required facilities that made my study possible.  
I also would like to acknowledge USM for giving me the postgraduate fellowship 
which has supported me during my study.  
I am also grateful to the Advanced Medical and Dental Institute (AMDI) for giving 
me the opportunity to carry out my study, and also to all laboratory members in 
AMDI who had assisted me during my project.  
My thanks also go to all members in EMAN laboratory in the School of 
Pharmaceutical Sciences, USM in particular Dr Abdalrahim F. A. Aisha and Dr 




My sincere thanks also go to Dr Hasnah Hashim, from AMDI for her statistical 
assistance, Associate Professor Moahmmed Al-Tikriti from Western University of 
Health Sciences, USA and Dr. Othman Abdullah from Department of Pathology, 
Sultan Abdul Halim Hospital, Kedah Malaysia, for their assistance in the 
interpretation of the histopathology slides. 
Sincere thanks also to Professor Abdel-Hamid Zaki and Dr Faisal M Al-Hassan for 
their support, assistance and guidance.  
 Also to all members of AMDI Animal House specially to Dr Nor Aini Saidin and Dr 
Nor Azlina Khalil.   
Last, but not the least, I would like to thank my brothers; Moad Saeed Ali 
Mohammed and Sedeeq Saeed Ali Mohammed and my close friend Mr Ahmad 
















TABLE OF CONTENTS 
 
TITLE ......................................................................... Error! Bookmark not defined. 
DEDICATION ............................................................................................................. ii 
ACKNOWLEDGEMENTS ........................................................................................ iii 
TABLE OF CONTENTS ............................................................................................. v 
LIST OF TABLES .................................................................................................... xiii 
LIST OF FIGURES .................................................................................................. xiv 
LIST OF ABBREVIATIONS ................................................................................... xvi 
LIST OF SYMBOLS .............................................................................................. xxiii 
ABSTRAK .............................................................................................................. xxiv 
ABSTRACT ........................................................................................................... xxvii 
CHAPTER 1   INTRODUCTION ............................................................................ 1 
1.1 Leukaemia ...................................................................................................................... 2 
1.2 Types of Leukaemias ..................................................................................................... 4 
1.2.1 Acute Myeloid Leukaemia (AML) ......................................................................... 4 
1.2.2 Acute Lymphoblastic Leukaemia (ALL) ................................................................ 4 
1.2.3 Chronic Lymphocytic Leukaemia (CLL) ................................................................ 5 
1.2.4 Chronic Myeloid Leukaemia (CML) ...................................................................... 6 
1.3 Therapeutic Challenges .................................................................................................. 6 
1.4 Natural Products are Main Sources for Anticancer Agents ........................................... 7 
1.4.1 Eurycoma longifolia Jack (E. longifolia) ................................................................ 8 
1.5 Justifications of the Study .............................................................................................. 9 
1.6 Hypothesis.................................................................................................................... 10 
1.7 Objectives of Study ...................................................................................................... 11 
vi 
 
1.7.1 Main Objective ...................................................................................................... 11 
1.7.2 Specific Objectives ............................................................................................... 11 
CHAPTER 2 LITERATURE REVIEW .................................................................... 12 
2.1 Origin of Blood Cells ................................................................................................... 13 
2.2 Haemopoietic Stem Cell Disorders .............................................................................. 15 
2.2.1 Classification ......................................................................................................... 15 
2.2.2 Leukaemia ............................................................................................................. 16 
2.2.2.1 Chronic Myeloid Leukaemia (CML) ............................................................. 16 
2.2.2.1.1 Molecular basis of CML ...................................................................... 17 
2.2.2.1.1.1 Philadelphia Chromosome ............................................................ 17 
2.2.2.1.1.2 The BCR/ABL Oncoprotein ......................................................... 20 
2.2.2.1.1.3 Regulatory Function of SRC Homology Domains ....................... 21 
2.2.2.1.2 Treatment of CML ............................................................................... 26 
2.2.2.1.2.1 Conventional Treatment ................................................................ 26 
2.2.2.1.2.2 Treatment with Imatinib ................................................................ 28 
2.2.2.1.2.3 Resistance to Imatinib ................................................................... 30 
2.3 Differentiation Therapies ............................................................................................. 32 
2.4 Apoptosis ..................................................................................................................... 37 
2.4.1 Definition and Concept of Evolution .................................................................... 37 
2.4.2 Types of Cell Death .............................................................................................. 39 
2.4.3 Mechanism and Regulation of Apoptosis ............................................................. 40 
2.5 Angiogenesis ................................................................................................................ 44 
2.5.1 Physiology and Pathology ..................................................................................... 44 
2.5.2 Angiogenesis Events ............................................................................................. 45 
2.5.3 Regulation of Angiogenesis .................................................................................. 47 
2.5.4 Tumor Angiogenesis ............................................................................................. 51 
2.5.5 Angiogenesis is a Promising Target for Cancer Treatment .................................. 55 
2.6 Drug Combination ....................................................................................................... 57 
vii 
 
2.7 Natural Products ........................................................................................................... 58 
2.7.1 General Consideration........................................................................................... 58 
2.7.2 Natural Products and Defense against Carcinogenesis ......................................... 59 
2.7.3 Eurycoma longifolia .............................................................................................. 60 
CHAPTER 3 MATERIALS AND METHODS ......................................................... 63 
3.1 Materials and Equipments ............................................................................................ 64 
3.2 Plant Materials ............................................................................................................. 70 
3.3 Anti-neoplastic Studies ................................................................................................ 71 
3.3.1 In vitro cytotoxicity Experiments.......................................................................... 71 
3.3.1.1 Cell lines and Cell Culture Maintenance ....................................................... 71 
3.3.1.2 Assessment of Anti-proliferative and Cytotoxic Activities ........................... 71 
3.3.1.2.1 Treatment with E. longifolia Extracts (F1–F4) .................................... 71 
3.3.1.2.2 Treatment with Eurycomanone ............................................................ 72 
3.3.1.2.3 Treatment with Imatinib ...................................................................... 72 
3.3.1.2.4 Treatment with Vincristine .................................................................. 72 
3.3.1.3 Cell Counts ..................................................................................................... 73 
3.3.1.4 MTS Assay ..................................................................................................... 73 
3.3.1.5 Assessment of Cytotoxicity of F273, F3 and F4 on Normal Cells ................ 74 
3.3.1.5.1 Mononuclear Cells (MNCs) Isolation .................................................. 74 
3.3.1.5.2 Treatment and MTS Assay .................................................................. 75 
3.3.1.6 Calculation of Growth Rate and Half Maximal Inhibitory Concentration 
(IC50) ......................................................................................................................... 75 
3.3.1.7 Anti-tumorigenicity ........................................................................................ 76 
3.3.1.7.1 Clonogenic Assay ................................................................................ 76 
3.3.2 In Vivo Experiments .............................................................................................. 77 
3.3.2.1 Source and Housing of the Experimental Animals ........................................ 77 
3.3.2.2 Preparation of K-562 Cell Line ...................................................................... 77 
3.3.2.3 Establishment of the Subcutaneous Tumor .................................................... 78 
3.3.2.3.1 Priming of Mice with Cyclophosphamide ........................................... 78 
3.3.2.3.2 Subcutaneous Injection of K-562 Cells ............................................... 78 
3.3.2.4 Treatment and Tumor Size Measurement ...................................................... 79 
3.3.2.5 Histological Examination ............................................................................... 79 
viii 
 
3.4 Toxicity Study .............................................................................................................. 80 
3.4.1 Experimental Animals........................................................................................... 80 
3.4.2 Treatment with TAF273........................................................................................ 80 
3.4.3 Collection of Blood Samples ................................................................................ 81 
3.4.4 Assessment of Haematological Parameters .......................................................... 81 
3.4.5 Assessment of Biochemical Parameters................................................................ 81 
3.4.6 Assessment of Histological Parameters ................................................................ 81 
3.5 Study of Mechanism .................................................................................................... 82 
3.5.1 Assessment of Apoptosis ...................................................................................... 82 
3.5.1.1 Annexin V-FITC/PI Assay ............................................................................. 82 
3.5.1.2 DNA Fragmentation ....................................................................................... 83 
3.5.1.3 Chromatin Condensation ................................................................................ 84 
3.5.1.4 Analysis of Human Apoptosis Pathway ......................................................... 84 
3.5.1.4.1 Cell Treatment and RNA Isolation and Quantification........................ 84 
3.5.1.4.2 RT2 ProfilerTM PCR Array ................................................................... 85 
3.5.1.4.3 cDNA Synthesis ................................................................................... 85 
3.5.1.4.4 Real Time PCR .................................................................................... 86 
3.5.2 Assessment of Cell Cycle ..................................................................................... 87 
3.5.2.1 Cell Cycle Analysis ........................................................................................ 87 
3.5.2.2 Analysis of Human Cell Cycle Pathway ........................................................ 88 
3.5.3 Assessment of TAF273 Effect on the Expression of BCR/ABL Mutation ........... 88 
3.5.3.1 Treatment of Cells .......................................................................................... 88 
3.5.3.2 RNA isolation ................................................................................................ 89 
3.5.3.3 Measuring the BCR/ABL Messenger Transcript ........................................... 90 
3.5.4 Assessment of Differentiation ............................................................................... 92 
3.5.4.1 Assessment of Erythroid Differentiation ....................................................... 92 
3.5.4.1.1 Treatment and RNA Isolation .............................................................. 92 
3.5.4.1.2 cDNA Synthesis ................................................................................... 93 
3.5.4.1.3 PCR Amplification of Gamma Globin and Beta Actin Genes ............. 93 
3.5.4.2 Assessment of Myeloid Differentiation ......................................................... 94 
ix 
 
3.5.4.2.1 Wright stain .......................................................................................... 94 
3.5.4.2.2 CD14 Expression ................................................................................. 95 
3.6 Drug Combination Study ............................................................................................. 96 
3.6.1 Calculation of Combination Index (CI) and Dose Reduction Index (DRI) .......... 96 
3.6.1.1 Treatment of K-562 Cells .............................................................................. 96 
3.6.2 Calculation of the Combination Effect ................................................................. 97 
3.6.3 Assessment of Drug Combination on K-562 Cell Morphology ............................ 97 
3.6.4 The In vivo Assessment of Drug Combination on Nude Mice ............................. 97 
3.7 Anti-Angiogenesis Study ............................................................................................. 98 
3.7.1 Ex vivo Rat Aortic Ring Assay ............................................................................. 98 
3.7.2 Assessment of Anti-proliferative Activity of TAF273 on HUVEC Cell Line ...... 99 
3.7.3 Cell Migration Assay .......................................................................................... 100 
3.7.4 Tube Formation Assay ........................................................................................ 100 
3.7.5 In vivo CAM Assay ............................................................................................. 101 
3.7.6 In Vivo Assessment of Tumor Angiogenesis in Nude Mouse Xenograft Model 102 
3.8 Anti-oxidant Study ..................................................................................................... 103 
3.8.1 Determination of Total Phenolics ....................................................................... 103 
3.8.2 Determination of Total Flavonoids ..................................................................... 103 
3.8.3 Evaluation of Free Radical Scavenging Activity ................................................ 104 
3.8.3.1 DPPH Assay ................................................................................................. 104 
3.8.3.2 ABTS Assay ................................................................................................. 105 
CHAPTER 4 RESULTS .......................................................................................... 106 
4.1 Anti-neoplastic Study ................................................................................................. 107 
4.1.1 In Vitro Experiments ........................................................................................... 107 
4.1.1.1 Assessment of Cytotoxcity by MTS Assay .................................................. 107 
4.1.1.2 Assessment of Anti-proliferative Activities by Cell Count ......................... 109 
4.1.1.3 Clonogenic Assay ........................................................................................ 112 
x 
 
4.1.2 In Vivo Experiments ............................................................................................ 114 
4.1.2.1 Tumor Size Measurement ............................................................................ 114 
4.1.2.2 Assessment of Hematoxylin/Eosin-Stained Tumor Sections ....................... 118 
4.2 Toxicity Study ............................................................................................................ 121 
4.2.1 Effect of TAF273 on Haematological Parameters .............................................. 121 
4.2.2 Effect of TAF273 on Biochemical Parameters ................................................... 123 
4.2.3 Effect of TAF273 on Histological Parameters .................................................... 124 
4.2.4 Effect of TAF273 on Body Weight, Food and Water Consumption .................. 126 
4.3 Study of Mechanism .................................................................................................. 128 
4.3.1 Assessment of Apoptosis .................................................................................... 128 
4.3.1.1 FITC- Annexin V/PI Assay .......................................................................... 128 
4.3.1.2 DNA Fragmentation ..................................................................................... 131 
4.3.1.3 Hoechst Staining .......................................................................................... 132 
4.3.2 Gene Expression in Human Apoptosis Pathway ................................................. 135 
4.3.3 Effect of TAF273 on Cell Cycle Distribution ..................................................... 138 
4.3.4 Gene Expression in Human Cell Cycle Pathway ................................................ 141 
4.3.5 Assessment of BCR/ABL Mutation Expression ................................................. 143 
4.3.6 Assessment of Differentiation ............................................................................. 144 
4.3.6.1 Effect of TAF273 on Erythroid Differentiation ........................................... 144 
4.3.6.2 Effect of TAF273 on Myeloid Differentiation ............................................. 146 
4.4 Drug Combination Study ........................................................................................... 148 
4.4.1 Assessment of the Combination Effect of TAF273-Imatinib Mixture ............... 148 
4.4.2 Assessment of Imatinib-TAF273 Combination on K-562 Cell Morphology ..... 151 
4.4.3 In vivo Assessment of TAF273-Imatinib Combination ...................................... 153 
4.5 Anti-angiogenic Study ............................................................................................... 154 
4.5.1 TAF273 Inhibits Sprouting of Microvessels in Rat Aortic Explants .................. 154 
4.5.2 TAF273 Inhibits Proliferation of HUVECs ........................................................ 157 
xi 
 
4.5.3 TAF273 Inhibits Migration of HUVECs ............................................................ 159 
4.5.4 TAF273 Inhibits Tube Formation in Human Endothelial Cells .......................... 161 
4.5.5 TAF273 Inhibits In vivo Neovascularization in Chick Embryo .......................... 164 
4.5.6 TAF273 Inhibits In vivo Angiogenesis in Xenograft Tumor .............................. 166 
4.6 Anti-oxidant study ..................................................................................................... 168 
4.6.1 Assessment of Total Phenolic and Flavonoid Contents ...................................... 168 
4.6.2 Free Radical Scavenging Effect of Fractions of E. Longifolia Root Extract ...... 169 
CHAPTER 5 DISCUSSION .................................................................................... 170 
5.1 Anti-neoplastic Studies .............................................................................................. 171 
5.1.1 Assessment of Cytotoxicity ................................................................................ 172 
5.1.2 In vivo Anti-neoplastic Effect of TAF273 .......................................................... 174 
5.2 Toxicological Studies ................................................................................................. 175 
5.3 Study of Mechanism .................................................................................................. 177 
5.3.1 Assessment of Apoptosis .................................................................................... 177 
5.3.1.1 Annexin-V/IP, DNA Fragmentation and Hoechst Stain .............................. 177 
5.3.1.2 Effect on Gene Expression of Apoptotic Pathway ....................................... 179 
5.3.2 Effect on Cell Cycle ............................................................................................ 181 
5.3.2.1 Cell Cycle Distribution ................................................................................ 181 
5.3.2.2 Effect on Gene Expression of Cell Cycle Pathway ...................................... 182 
5.3.3 Effect of TAF273 on the Expression of BCR/ABL Mutation ............................ 184 
5.3.4 Assessment of Differentiation ............................................................................. 185 
5.3.4.1 Effect on Erythroid Differentiation .............................................................. 185 
5.3.4.2 Effect on Myeloid Differentiation ................................................................ 186 
5.4 Effect of TAF273-Imatinib Combination .................................................................. 187 
5.5 Assessment of Anti-angiogenic activity .................................................................... 188 
5.6 Assessment of Anti-oxidant Activity ......................................................................... 192 
5.7 Summary and Conclusion .......................................................................................... 193 
5.8 Limitations ................................................................................................................. 195 
xii 
 
5.9 Future Research Directions ........................................................................................ 196 
REFERENCES ......................................................................................................... 197 
APPENDICES ......................................................................................................... 228 
Appendix A StdSens analysis protocol .................................................................... 228 
Appendix B Description of the Leukaemic Cell Lines Used in This Study ............ 234 
B1: Description of K-562 Cell Line. ........................................................................ 234 
B2: Description of HL-60 Cell Line ........................................................................ 235 
B3: Description of Kasumi-1 Cell Line ................................................................... 236 
Appendix C Plant Extraction ................................................................................... 237 
LIST OF PUBLICATIONS ..................................................................................... 240 
















LIST OF TABLES 
 
Table 2-1 Comparison of morphological features of apoptosis and necrosis ............ 40 
Table 2-2 Stimulators and inhibitors of angiogenesis ................................................ 47 
Table 3-1 List of Chemicals ....................................................................................... 64 
Table 3-2 List of Reagents ......................................................................................... 65 
Table 3-3 List of Kits ................................................................................................. 66 
Table 3-4 List of Instruments ..................................................................................... 67 
Table 3-5 Cycling profile in BCR/ABL mutation amplification ............................... 90 
Table 4-1 Half maximal inhibitory concentration (IC50) values of various fractions 
of E. longifolia root methanolic extract on different leukaemia cell lines and MNCs.
 .................................................................................................................................. 108 
Table 4-2 Haematology results of nude mice treated orally with TAF273 (200 
mg/kg) for 16 days. .................................................................................................. 121 
Table 4-3 Biochemical results of nude mice treated orally with TAF273 (200mg/kg) 
for 16 days. ............................................................................................................... 123 
Table 4-4 Food and water consumption measurements in the treated and untreated 
mice .......................................................................................................................... 127 
Table 4-5 Effect of treatment with TAF273 on K-562 cell cycle distribution ......... 139 
Table 4-6 Dose-effect relationship parameters for imatinib and TAF273 in K-562 
cells .......................................................................................................................... 149 
Table 4-7 Effect of imatinib-TAF273 combination on the combination index (CI) at 
different effect levels................................................................................................ 149 
Table 4-8 Anti-oxidant activity of fractions from E. longifolia root methanolic 




LIST OF FIGURES 
 
Figure 2.1 Schematic diagram of haematopoiesis...................................................... 14 
Figure 2.2  Schematic illustration of t(9;22)(q34;q11), break points and  ABL/BCR 
chimeric proteins in CML .......................................................................................... 18 
Figure 2.3  Functional domains in p160BCR, p145ABL and p210BCR-ABL. ........ 22 
Figure 2.4  Physiologic regulation by the normal ABL protein and deregulation by 
BCR/ABL of key cellular processes. ......................................................................... 23 
Figure 2.5  Signal transduction pathways affected by BCR/ABL. ............................ 25 
Figure 2.6 Diagrammatic presentation of normal haematopoiesis and 
leukaemiogenesis ....................................................................................................... 32 
Figure 2.7 Differentiation therapy in APL. ................................................................ 34 
Figure 2.8 The evolution of the concept of apoptosis. ............................................... 38 
Figure 2.9 Schematic representation of apoptotic events........................................... 42 
Figure 2.10 Schematic illustration of regulatory proteins involved in apoptosis. ..... 43 
Figure 2.11 New blood vessel formation. .................................................................. 46 
Figure 2.12 The angiogenic balance. ......................................................................... 50 
Figure 2.13 Effect of hypoxia on tumor growth. ....................................................... 52 
Figure 2.14 Angiogenesis and tumor metastasis ........................................................ 54 
Figure 2.15 Targets of anti-angiogenic therapeutic drugs. ........................................ 56 
Figure 2.16 Eurycoma longifolia tree. ....................................................................... 62 
Figure 3.1 The pipetting scheme in BCR/ABL mutation amplification .................... 91 
Figure 4.1  Effects of TAF 273 and eurycomanone on the proliferation of K-562 and 
HL-60 cells. .............................................................................................................. 110 
Figure 4.2 Effect of F1, F3 and F4 on growth rate of K-562 and HL-60 cells. ....... 111 
Figure 4.3 Colony morphology and dose-response curves. ..................................... 113 
Figure 4.4 Effect of oral administration of TAF273 on K-562-subcutaneous tumor in 
nude mice. ................................................................................................................ 115 
Figure 4.5 Effect of intraperitoneal administration of TAF273 on K-562-
subcutaneous tumor in nude mice. ........................................................................... 116 
Figure 4.6 The differences in tumor size in different mice groups. ......................... 117 
Figure 4.7 Effect of TAF273 on the histological appearance of subcutaneous tumor 
of K-562 xenograft in nude mice model. ................................................................. 119 
Figure 4.8 TAF273 induced necrosis in subcutaneous tumor of K-562 xenograft in 
nude mice model. ..................................................................................................... 120 
Figure 4.9 Effect of treatment with TAF273 on blood cell morphology. ................ 122 
Figure 4.10 Comparative histology of kidney, liver, and spleen from control mice (A, 
D and E, respectively) and from TAF273-treated mice (B, D and F, respectively). 125 
Figure 4.11 Effect of TAF273 on body weight. ....................................................... 127 
Figure 4.12 TAF273 induced externalization of phosphatidylserine. ...................... 130 
Figure 4.13 Effect of TAF273 on DNA fragmentation of K-562 cells (left) and HL-
60 cells (right). ......................................................................................................... 131 
xv 
 
Figure 4.14 Nuclear morphology and apoptotic index of K-562 cells. .................... 133 
Figure 4.15 Nuclear morphology and apoptotic index of HL-60 cells. ................... 134 
Figure 4.16 RNA quality and integrity. ................................................................... 136 
Figure 4.17 Effect of TAF273 on expression profile of apoptosis-related genes in K-
562 cells. .................................................................................................................. 137 
Figure 4.18 TAF273 caused G1 and S cell cycle arrest in K-562 cells. .................. 140 
Figure 4.19 Effect of TAF273 on expression profile of cell cycle-related genes in K-
562 cells. .................................................................................................................. 142 
Figure 4.20 Effect of TAF273 on the expression of BCR/ABL mutation. .............. 143 
Figure 4.21 Expression of γ-globin gene in K-562 cells maintained with and without 
TAF273 at various concentrations and time points. ................................................ 145 
Figure 4.22 Effect of TAF273 on myeloid differentiation of HL-60. ...................... 147 
Figure 4.23 TAF273-imatinib combination plots. ................................................... 150 
Figure 4.24 Effect of treatment with TAF273, imatinib and their combination on K-
562 cell morphology. ............................................................................................... 152 
Figure 4.25 Toxic effect of TAF273-imatinib combination in nude mice. .............. 153 
Figure 4.26 Anti-angiogenic effect of fractions of E. longifolia root extract. ......... 155 
Figure 4.27 Effect of TAF 273, F3 and F4 on microvessel formation. ................... 156 
Figure 4.28 Effect of TAF 273 on HUVEC cells proliferation................................ 158 
Figure 4.29 Effect of TAF273 on HUVEC cell migration....................................... 160 
Figure 4.30 Effect of TAF273 on HUVECs differentiation. ................................... 162 
Figure 4.31 Graphical illustration of dose-dependent inhibitory effect of TAF273 on 
the height and width of capillary-like structures of HUVECs. ................................ 163 
Figure 4.32 Inhibitory effect of TAF273 on neovascularization in chorioallantoic 
membrane of chick embryo. ..................................................................................... 165 
Figure 4.33 Anti-angiogenic effect of TAF273 on xenograft tumor derived from K-
562 cell line. ............................................................................................................. 167 
Figure 4.34 Total flavonoids and total phenolic contents of partial fractions of E. 




 LIST OF ABBREVIATIONS 
 




AC Apoptotic cells 
AI Apoptotic index 
ALL Acute lymphoblastic leukaemia 
ALT Alanine aminotransferase 
AML Acute myeloid leukaemia 
AP Accelerated phase 
APL Acute promyelocytic leukaemia 
ARG  Abelson-related gene   
AST Aspartate aminotransferase 
ATRA all trans retinoic acid 
B B lymphocyte 
Baso Basophil 
Bax Bcl-2-associated X 
BC Blast crisis 
Bcl B-cell lymphoma 
BCR Breakpoint cluster region 
BFU-E Erythroid burst forming unit 
BIRC5 Baculoviral inhibitor of apoptosis repeat-
containing 5 
BM Basement membrane 
BV Blood vessel 
CAM Chorioallantoic membrane 
xvii 
 
CBL Casitas B-lineage lymphoma pro-oncogene 
protein 
CCND1 Cyclin-D1 
CCNE1 Cyclin E1 
CCyR Complete cytogenetic response 
CD Cluster of differentiation 
CDKN1B Cyclin-dependent kinase inhibitor 1B 
cdks Cyclin- dependent kinases 
CEN Checken erythrocyte nuclei 
CFU-GM Granulocyte–macrophage colony forming 
unit. 
CHR Chronic heart disease 
CI Combination index 
c-Kit Proto-oncogene with tyrosine kinase 
activity 
CLL Chronic lymphocytic leukaemia 
CLP Common lymphoid progenitor 
CML Chronic myelocytic leukaemia 
CMP Common myeloid progenitor 
C-Myc Cellular Proto-oncogene myc 
CP chronic phase 
CRKL CRK-like protein 
CT Threshold cycle 
DBL Diffuse B-cell lymphoma oncogene 
DMSO Dimethyl sulfoxide  
DNA  Deoxyribonucleic acid 
DPPH 2,2-diphenyl-1-picrylhydrazyl 
DRI Dose reduction index 
xviii 
 
E. longifolia Eurycoma longifolia 
EC Endothelial cell 
ECGS Endothelial cell growth supplements 
ECM extracellular matrix 
ECM Endothelial cell medium 
ED Effective dose  
Eo Eosinophil 
F1 Fraction 1 
F3 Fraction 3 
F4 Fraction 4 
FBS Fetal bovine serum 
FGF Fibroblast growth factors 
FITC Fluorescein isothiocyanate 
G1 G1 phase 
G2 G2 phase 
GADD45A Growth arrest and DNA damage-45 alpha 
GAP Guanosine triphosphatase-activating 
function protein 
GDP Guanosine diphosphate 
GEF GDP-GTP exchange factor 
GIR Growth inhibition rate 
GRB2 Growth factor receptor-bound protein 2 
GTP guanosine triphosphate 
H&E Hematoxylin and eosin 
HDAC Histone deacetylase 
HGF Hepatocyte growth factor 
HIFs Hypoxia inducible factors 
xix 
 
HIV Human Immunodeficiency Virus 
HLA Human leukocyte antigens 
HUVECs Human umbilical vein endothelial cells 
IC50 Half maximal inhibitory concentration 
IHD Ischemic heart diseases 
IL Interleukin 
INF-α Interferon-ɑ 
IP Intraperitoneal  
JAK Janus kinase 
JNK Jun N-terminal Kinase 
kb Kilo base 
LTA Lymphotoxin-alpha 
MAP Mitogen-activated protein 
MC Mitotic cells 
MCH Mean corpuscular hemoglobin 
MCHC Mean corpuscular haemoglobin 
concentration 
MCV Mean corpuscular volume 
MCyR Major cytogenetic response 
MDS Myelodysplastic syndrome  
mg Milligram 
mgQE/g Quercetin equivalent per g 
MMPs Matrix metalloproteinases 
MNCS Mononuclear cells 
Mono Monocyte 






NADH Nicotinamide adenine dinucleotide 
NC Necrotic cells 
NCEs Newly chemical entities 
N-CoR Nuclear receptor corepressor 
 Neut  Neutrophil 
P53 Tumor suppressor protein 53 
PAs Plasminogen activators 
PBS Phosphate buffer saline 
PC Pericytes 
PCNA Proliferating cell nuclear antigen 
PCR Polymerase Chain Reaction 
PCV Polycythemia vera  
PD-ECGF Platelet-derived endothelial cell growth 
factor 
PDGF Platelets derived growth factor 
PDGFR Platelet-derived growth factor receptor 
PE Plating efficiency 
PEDF Pigment epithelium-derived factor 
Ph Philadelphia 
PI Propidium iodide 
PI3K Phosphatidylinositol 3-kinase 
PlGF Placenta growth factor 
PLT Platelets 
PS Phosphatidylserine 
QC Quality control 
qRT-PCR Quantitative real time PCR 
xxi 
 
RAC RAS-like GTPase 
RAR Retinoic acid receptor 
RARɑ Retinoic acid receptor alpha 
RAS Rat sarcoma 
RBC Red blood cells 
RNA Ribonucleic acid 
RPMI Roswell Park Memorial Institute medium 
RT Room temperature 
S Synthetic phase 
SCD Sickle cell disease 
SCT Stem cell transplant 
SD Standard deviation  
SF Survival fraction 
SH1 SRC homology domain1 
SH2 SRC homology domain2 
SH3 SRC homology domain3 
SHC SRC homology 2-containing protein 
SMART Complex and silencing mediator for RAR 
and TR 
SRC Sarcoma 
STAT Signal transducers and activators of  
transcription 
T T lymphocyte 
TAF273 Fraction 2 
TGF Transforming growth factor 
TNF-a Tumor necrosis factor alpha 




TNFRSF9 Tumor necrosis factor receptor superfamily 
member 9  
TRADD Tumor necrosis factor receptor type 1-
associated DEATH domain 
TRAF2 TNF receptor-associated factor 2 
TRAF4 TNF receptor-associated factor 4 
VC Viable cells 
VEGF Vascular endothelial growth factor 
VEGI Vascular endothelial growth inhibitor 
wt-HIF- 1ɑ Wild-type hypoxia-inducible factor 1 alpha 
mg/kg Milligram/kilogram 
µg/ml Microgram/millilitre  
xxiii 
 
LIST OF SYMBOLS 
 
ɑ Alpha  
γ Gamma  
β Beta  
˂ Less than 






















  KAJIAN ANTINEOPLASTIK MENGGUNAKAN EKSTRAK 




 Aktiviti antineoplastik ekstrak akar Eurycoma longifolia telah dikaji ke atas 
penyakit leukemia menggunakan model in vitro dan in vivo. Empat subjenis spara 
tulen (F1, TAF273, F3 dan F4) ekstrak methanol akar E. longifolia asli yang 
diperolehi secara resin kromatografi disaring untuk aktiviti-aktiviti antileukemia, 
antiangiogenesis dan antioksidan. Aktiviti antileukemia telah diuji secara in vitro 
dengan lini sel leukemia K-562, HL-60 dan Kasumi-1 sementara kajian in vivo 
dengan K-562-xenograf menggunakan model tikus.  Mekanisma tindakan, kombinasi 
kesan ubat dan toksik oleh TAF273T juga telah dikaji.  
  Kajian ini menunjukkan bahawa TAF273 mempunyai kesan sitotoksik yang 
paling efektif. Ia berpotensi untuk merencat pertumbuhan sel-sel K-562 dan HL-60 
dengan nilai–nilai IC50 sebanyak 19 ± 3 dan 15 ± 2 µg/ml masing-masing. TAF273 
merencat pertumbuhan sel-sel K-562 dan HL-60 (95%). Kesan sitotoksik TAF273 ke 
atas K-562 ditunjukkan juga dengan perencatan pertumbuhan koloni yang ketara dan 
kadar penurunan survival yang ekstrim (<0.5%). 
 Pemberian TAF273 secara intraperitoneal juga merencat pertumbuhan 
tumor di dalam K-562- xenograf tikus dengan kadar perencatan sebanyak 80.8% 
berbanding dengan control (P = 0.021). Tambahan pula, pewarnaan 
Hematoxylin/Eosin ke atas keratan tikus yang dirawat dengan TAF273 menunjukkan 
peningkatan yang ketara di dalam indeks apoptosis dan nekrosis (P < 0.001) serta 
penurunan yang jelas pada kehadiran saluran darah di dalam tumor berbanding 
dengan kontrol.  
xxv 
 
 Kajian ini dengan jelas menunjukkan kesan sitotoksik adalah akibat 
daripada aruhan kepada apoptosis dan perencatan kitaran sel.  TAF273 mengaruh 
kepada apoptosis dalam sel-sel K-562 dan HL-60 mengikut dos dan masa. 
Peningkatan apoptosis dibuktikan melalui ‘externalization phosphatidylserine’, 
kondensasi kromatin (P < 0.01) dan fragmentasi DNA. Analisa laluan apoptosis 
dalam sel 562 yang dirawat dengan TAF273 menunjukkan ekspresi pelbagai gen 
yang mengawal apoptosis juga turut terlibat. LTA, TNFRSF9, TNFSF10, CD70, 
TP53, TRADD, TRAF2 dan TRAF4 secara signifikan menunjukkan ‘upregulated’ 
sementara AKT1, BCL2, BID, BNIP2, BNIP3, NOD1, BAX, BCL2L11, BCL2L2, 
BFAR dan BRAF secara signifikan menunjukkan ‘down-regulated’ berbanding 
dengan kontrol (P < 0.01). Profil ekspresi gen mencadangkan bahawa mekanisma 
ekstrinsik and intrinsik terlibat di dalam aruhan apoptosis oleh TAF273.  
 Analisa aktiviti taburan kitaran sel dalam sel K-562 menunjukkan bahawa 
TAF273 menyekat pusingan sel pada fasa G1, S dan G2. Ini disokong oleh analisa 
laluan kitaran sel yang menunjukkan ‘up-regulation’ CDKN1B, GADD45A, 
GTF2H1, HERCS, HUS1 dan SERTAD1 serta, menunjukkan ‘down-regulation’  
BCL2, CCNE1 dan PCNA berbanding dengan kontrol (P < 0.01). 
 Tambahan pula, TAF273 meningkatkan aktiviti sitotoksik imatinib ke atas 
sel-sel K-562. Kombinasi TAF273 dan imatinib menunjukkan kesan sinergistik ke 
atas sel K-562 pada nilai-nilai ED50, ED75 dan ED90. Kesan sinergistik ini 
menurunkan indeks dos sehingga 5 untuk imatinib dan kepada 2.5 untuk TAF273. 
Penurunan dos imatinib (sebanyak 5 kali) boleh mengurangkan kesan toksiknya. 
 Walaupun TAF273 menunjukkan kesan sitotoksik pada pada sel-sel leukemia, 
penting dinyatakan bahawa ia tidak menunjukan perubahan kepada parameter-
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parameter hematologi, biokimia dan histologi apabila diambil secara oral sebanyak 
200 mg/kg. Penemuan ini disokong oleh kesan sitotoksik TAF273 yang rendah ke 
atas sel-sel mononuklear periferi  normal (IC50 180 µg/ml). Ini menunjukkan 
terdapat kesan sitotoksik selektif kepada sel-sel leukemia. 
 Di samping kesan sitotoksik, TAF273 juga menunjukkan aktiviti 
antiangiogenik yang kuat dan ini ditunjukkan dengan  perencatan yang signifikan 
dalam penyebaran salurdarah mikro di dalam aorta tikus dengan IC50  sebanyak 11.5 
μg/ml. TAF273 menunjukkan perencatan yang ketara (63.13%) pada pertumbuhan 
salur darah baru dalam membran ‘chorioallantoic’ embrio ayam. Kajian histologi ke 
atas tumor mendedahkan pengurangan yang jelas di dalam penyebaran salurdarah 
berbanding dengan kontrol (P<0.01). TAF273 dalam kajian in vitro merencat secara 
signifikan proses angiogenesis melalui langkah-langkah seperti proliferasi, migrasi 
dan pembezaan pada HUVECs. 
 Sebagai kesimpulan, penyeragaman komponen TAF273 daripada ekstrak 
methanolic akar E. longifolia berpotensi sebagai agen antitumor dan 
berkemungkinan dijadikan sebagai agen kemoterapi untuk rawatan leukaemia jenis 






ANTI-NEOPLASTIC STUDIES OF STANDARDIZED ROOT 




   The anti-neoplastic activity of root extracts from Eurycoma longifolia was 
investigated towards leukaemia using in vitro and in vivo models. Four partially 
purified sub-fractions (F1, TAF273, F3 and F4) derived from resin chromatography 
of the crude methanolic extract of E. longifolia roots were screened for the anti-
leukaemic, anti-angiogenic and anti-oxidant activities. The in vitro anti-leukaemic 
activity was tested using K-562, HL-60 and Kasumi-1 leukaemic cell lines whereas 
in vivo anti-leukaemic activity was tested using K-562-xenograft mice model. The 
toxicity, mechanism of action and drug combination effect of TAF273 were also 
investigated.  
   The results showed that TAF273 was the most effective cytotoxic fraction. It 
potentially inhibited the growth of K-562 and HL-60 cells with IC50 values of 19 ± 3 
and 15 ± 2 µg/ml, respectively. The exposure of K-562 and HL-60 cells to TAF273 
resulted in a significant growth inhibition (95%). The cytotoxicity of TAF273 on K-
562 cells was also indicated by the remarkable inhibition of colony formation and the 
extremely low survival rates (˂ 0.5%). 
 Intraperitoneal administration of TAF273 also significantly inhibited tumor 
growth in the K-562-xenograft mice with growth inhibition rate of 80.8% compared 
with control (P = 0.021). In addition, Hematoxylin/Eosin stained sections from 
TAF273-treated mice revealed significant increase in the apoptotic and necrotic 
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indices (P ˂ 0.001) and a remarkable reduction of intratumor blood vessels compared 
with control. 
   This study clearly indicates that the cytotoxic effect of TAF273 is most likely 
due to the induction of apoptosis and cell cycle arrest. TAF273 induced apoptosis in 
K-562 and HL-60 cells in a dose and time-dependent manner. The induction of 
apoptosis was evidenced by significant phosphatidylserine externalization, chromatin 
condensation (P ˂ 0.01) and DNA fragmentation. Furthermore, analysis of the 
apoptotic pathway in K-562 cells treated with TAF273 demonstrated that the 
expression of various genes regulating apoptosis was also affected. LTA, TNFRSF9, 
TNFSF10, CD70, TP53, TRADD, TRAF2 and TRAF4 were significantly up-
regulated, while AKT1, BCL2, BID, BNIP2, BNIP3, NOD1, BAX, BCL2L11, 
BCL2L2, BFAR and BRAF were significantly down-regulated compared with 
control (P ˂ 0.01). The gene expression profile suggested that the extrinsic and 
intrinsic mechanisms were involved in TAF273-induced apoptosis.  
   Analysis of cell cycle distribution in K-562 cells showed that TAF273 induced 
cell cycle arrest at the G1, S and G2 phases. This was supported by an analysis of the 
cell cycle pathway which demonstrated up-regulation of CDKN1B, GADD45A, 
GTF2H1, HERCS, HUS1 and SERTAD1, and down-regulation of BCL2, CCNE1 
and PCNA compared with control (P ˂ 0.01). 
       Furthermore, TAF273 enhanced the cytotoxic activity of imatinib on K-562 
cells. TAF273-imatinib combination showed a synergistic effect at ED50, ED75 and 
ED90 values. This synergistic effect resulted in a dose reduction index of up to five 
(5) times for imatinib and up to 2.5 for TAF273. The reduction in the dose of 
imatinib decreases its toxicity.  
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Despite the cytotoxicity of TAF273 on the leukaemic cells, it is important to 
note that TAF273 showed no remarkable alterations in the haematological, 
biochemical or histological parameters when taken orally at 200 mg/kg. These 
findings were also supported by the extremely low cytotoxicity of TAF273 on 
normal peripheral blood mononuclear cells (IC50 180 µg/ml). This indicates a 
selective cytotoxicity towards the leukaemic cells. 
Beside the cytotoxicity, TAF273 also revealed a potent anti-angiogenic 
activity as indicated by the significant suppression in the sprouting of microvessels in 
rat aorta with IC50 value of 11.5 μg/ml. TAF273 showed remarkable inhibition 
(63.13%) of neovascularization in the chorioallantoic membrane of a chick embryo. 
Tumor histology also revealed a marked reduction in the extent of vascularization 
compare with control (P ˂ 0.01). In vitro, TAF273 significantly inhibited the major 
angiogenesis steps, such as proliferation, migration and differentiation, of HUVECs.  
      In conclusion, the standardized TAF273 fraction of E. longifolia  root 
methanolic extract showed promising anti-tumor activity and may be a potential 



















1.1   Leukaemia 
   The term “leukaemia” comprises a diverse range of biologically-distinct 
diseases that affect the blood and bone marrow (Xie et al., 2003). The bone marrow 
cells are characterized by increased and uncontrolled proliferation of clone cells 
(Bock et al., 2007; Lichtman, 1995; Shah et al., 1998). The blockage of leukaemic 
cells at the disease’s early stages of development and failure of these cells to mature 
into functional cells are the main abnormality (Nowak et al., 2009).  
   Aetiologically, leukaemia results from a sequential series of mutational events, 
including: amplification, point mutations and most frequently, specific chromosome 
breakages and fusions that cause inappropriate associations of two different genes 
occurring in the bone marrow stem cells. These stem cells are normally capable of 
self-renewal and serve to sustain the population of cells by differentiating into the 
different blood cell lineages (Gilliland et al., 2004; Yu et al., 2011). 
   Leukaemia can also develop from other disorders, such as myelodysplastic 
syndrome (MDS), aplastic anemia, monoclonal B cell disorder and HIV infection 
(Aboulafia et al., 2002; Marti et al., 2005). Other diseases that can transform into 
leukaemia include idiopathic myelofibrosis, primary thrombocythaemia, 
polycythemia vera (PCV) and clonal sideroblastic anemia (Cervantes et al., 2005; 
Lichtman, 2005).  
   Environmental factors such as exposure to radiation or chemotherapy may be 




   Leukaemia is an economical burden and a health care problem worldwide 
(Redaelli et al., 2004). It occurs among all ages and can appear as early as a few 
weeks of birth to a late age (Meadors, 1956).  
The incidence of leukaemia in the world is about 1 per 100,000 per year (Parkin 
et al., 1999). In the United States of America (USA), 30,800 individuals were 
diagnosed with leukaemia and of that number, 21,700 individuals died of the disease 
(Jemal et al., 2002). Additionally in the USA, the incidence of acute leukaemia in the 
first year of life is 30 cases per million of live births. Also the annual incidence of 
acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML) is 20, 
and 10.6 cases per million, respectively (Felix and Lange, 1999).  
 In developed countries, (Stiller and Parkin, 1996) reported that acute leukaemias 
affect between 30–45 million children annually. 
 In Malaysia, leukaemia ranked fourth among cancers in males and fifth in 
females with an age standardized incidence rate (ASR) of 3.5 in males and 2.7 in 
females (Zainal Ariffin and Nor Saleha, 2011). 
    Leukaemia is clinically and pathologically subdivided into four major subtypes: 
acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), chronic 





1.2   Types of Leukaemias 
1.2.1   Acute Myeloid Leukaemia (AML)  
   Acute myeloid leukaemia (AML) refers to a group of distinct subtypes that 
differ with respect to pathogenesis, genetic abnormalities, clinical features, response 
to therapy and prognosis (Löwenberg et al., 2003). AML has an incidence of about 5 
cases/100,000 individuals/year and accounts for about 80% of acute leukaemia in 
adults, and 15–20 %  in children (Deschler and Lübbert, 2006). In children, AML is 
characterized by a high white blood cell count and bulky extramedullary disease. The 
survival rate, however, is better than in older people (Felix and Lange, 1999). 
   The presence of more than 20% leukaemic blasts in a bone marrow aspirate is 
essential for a definitive diagnosis of acute leukaemia (Vardiman et al., 2009). The 
AML stem cell has been defined immunophenotypically as CD34+, CD38–, HLA–
DR–, CD71-, CD90-, CD117–, and CD123+. The expression of CD90, CD117 and 
CD123 on the AML stem cell distinguishes it from the normal haematopoietic stem 
cell (HSC) (Gilliland et al., 2004; Reya et al., 2001). AML is the consequence of 
more than one mutation, such as point mutations, gene rearrangements and/or 
chromosomal translocations (Gilliland et al., 2004).  
1.2.2   Acute Lymphoblastic Leukaemia (ALL) 
Acute lymphoblastic leukaemia (ALL) is a clonal expansion of genetically 
altered lymphoblasts. It is the most frequent cancer in childhood, accounting for 23% 
of cancers diagnosed among children under 15 years of age. In the USA, it is 
estimated that the annual incidence rates per million are 77, and 17 at the age of 2 
years and 14 years respectively (van den Berg and van der Lelie, 2000). ALL 
accounts for approximately 20% of adult leukaemia (Champlin and Gale, 1989). 
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Despite the high incidence rate of ALL in the childhood group, the cure rate, 
however, is high in this group (van den Berg and van der Lelie, 2000).  
   In contrast, the  results of treatment in adults with ALL remain poor despite the 
application of strategies used successfully in children (Copelan and McGuire, 1995). 
ALL, particularly T-cell ALL, is associated with the expression of one or more of the 
following specific oncogenes: LYL1, LMO2, HOX11, TAL1, LMO1, HOX11L2, 
and MLL-ENL (Pui et al., 2004). 
1.2.3   Chronic Lymphocytic Leukaemia (CLL) 
   Chronic lymphocytic leukaemia (CLL) is characterized by the proliferation and 
accumulation, in the bone marrow and lymphoid organs, of immunologically non-
competent B–lymphocytes arrested at the early stages of differentiation (Dameshek, 
1967). CLL is rarely seen in people younger than 40 years and is manifested as 
immune disorders, such as hypogammaglobulinemia and auto immune phenomena 
(Montserrat and Rozman, 1995).  
   CLL occurs most frequently in Western countries, with an annual incidence rate 
of 2.5 cases/100,000 individual. CLL accounts for 30% of all leukaemias in Western 
populations, while it accounts for 3–5% in Asian populations (Finch and Linet, 
1992). Its aetiology is not yet fully understood.  
   The involvement of bcl-1 and bcl-2 oncogenes in the development of leukaemia 
is controversial. The t(14;19) is rare and no relationship with viruses or genes has 
been demonstrated (O'Brien et al., 1995; Montserrat and Rozman, 1995).  
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1.2.4   Chronic Myeloid Leukaemia (CML) 
   Chronic myeloid leukaemia (CML), a malignant disease of the human 
haematopoietic stem cell results from the BCR/ABL gene rearrangement. It is 
characterized by a marked increase in granulocytes, marked bone marrow 
hyperplasia, and splenomegaly (Au et al., 2009; Lawler et al., 1974). 
   CML accounts for approximately 15% of all leukaemias. CML has a worldwide 
incidence of 1–2 per 100,000 (Epstein et al., 1999). In the USA, about 5,000 cases 
are diagnosed annually and 470 patients will die from the disease (O'Brien et al., 
2009; Terasawa et al., 2010).  
   The Philadeplphia (Ph) chromosome is a cytogenetic hallmark of this disease. It 
results from reciprocal translocation t(9;22)(q34;q21) found specifically in the 
leukaemic cells of over 90% of CML patients (Naumann and Decker, 2003). The 
expression of the constitutively activated tyrosine kinase (p210BCR/ABL) is necessary 
and sufficient to develop CML (Kurzrock et al., 2003; Calabretta and Perrotti, 2004). 
1.3   Therapeutic Challenges 
Chemotherapy is a very important approach in the treatment of leukaemias. 
Over the past three decades, treatment of leukaemia with chemotherapeutic agents 
has achieved highly successful survival rates, with complete haematological and 
cytogenetic responses.  
   Imatinib, an Abl kinase inhibitor, induces complete cytogenetic responses in 
more than 80% of newly diagnosed CML patients (Corbin et al., 2011). This 
improvement is basically attributed to an increase in the number and activity of 
therapeutic agents recently produced and using multi-agent chemotherapy rather than 
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single-agent therapeutic strategies. However, the emergence of resistance and relapse 
to frontline anti-leukaemic drugs brings difficulties in treatment of this disease.  
   A relapse of up to 40% has been reported in patients with AML who had 
responded successfully to initial therapy (Reddy and Perkins, 2004; Sievers et al., 
2003).  
In CML, 60% of patients treated with imatinib showed relapse (Martin et al., 
2006). Resistance to imatinib, a frontline chemotherapeutic agent against CML, has 
been reported recently (Corbin et al., 2011; Quintas-Cardama et al., 2007). 
Cytogenetic resistance is reported in 15–25% of patients. Cytogenetic resistance is 
defined as failure to achieve any level of cytogenetic response, major cytogenetic 
response (MCyR), or complete cytogenetic response (CCyR) at 6, 12 and 18 months 
respectively (O'Brien et al., 2009).   
   Developing strategies to overcome the resistance to frontline 
chemotherapeutical agents of leukaemias pose a challenge in treating this disease. 
Thus the search for new novel compounds that can overcome or reverse this 
resistance become necessary. There exist several naturally occurring compounds in 
certain vegetables and herbs that exhibit chemopreventive properties (Reddy et al., 
2003). 
1.4   Natural Products are Main Sources for Anticancer Agents 
   Over the years, natural products have provided a rich source of compounds that 
have been used in medicine, pharmacy and biology (Gordaliza, 2007). Natural 
healing agents from microorganisms, plants and animals were eventually discovered, 
and for hundreds of years have been refined in the treatment and prevention of 
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complex human diseases. Doctors and researchers today continue to use these natural 
phenomena in modern medicine (Nobili et al., 2009; Pan et al., 2009).  
   Plants are an important source of new natural products; to the field of medicine, 
they continue to provide pools teeming with new molecules. In fact, medicinal herbs 
are still used in primary health care, despite the fact that the last few centuries have 
witnessed a revolution in synthetic variants (Pan et al., 2009). Natural products 
constitute around 60% of cancer chemotherapeutic drugs currently used today 
(Gordaliza, 2007). 
   Researchers are constantly searching for new recipes for anti-tumor drugs, and 
their searches usually begin with natural products. 
1.4.1   Eurycoma longifolia Jack (E. longifolia) 
   Eurycoma longifolia Jack from the family Simaroubaceae is commonly found in 
South East Asia (SEA) including Thailand, Malaysia, Laos, Cambodia, Myanmar 
and Indo-China (Osman et al., 2003). It is a slender, evergreen flowering plant and it 
is known locally as ‘Tongkat Ali’ or ‘Pasak Bumi’ in Malaysia and Indonesia (Bhat 
and Karim, 2010; Wernsdorfer et al., 2009). This plant has gained a considerable 
reputation as a traditional medicine; its local use has been a sorted list of treatments, 
including aiding childbirth, as an aphrodisiac and as a treatment for dysentery. 
   E. longifolia has many compounds that are biologically active, with anti-
plasmodial activity (Chan et al., 2004). Several classes of compounds have been 
isolated and identified, including quassinoids, β-carboline, triterpene tirucallane type, 
alkaloids, canthin-6-one alkaloids, biphenylneolignan and squalene derivatives 
(Mahfudh and Pihie, 2008).  
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1.5   Justifications of the Study    
Cancer has risen to the top in terms of causes of death in both 
developed countries and developing countries (Jemal et al., 2011). In 
Malaysia, leukaemia accounts for 4.1% of all cancers (Zainal Ariffin and Nor 
Saleha, 2011). 
 The emergence of resistance to and high toxicity of currently used 
anti-leukaemic drugs such as imatinib creates difficulties for the treatment of 
leukaemia. Therefore, a search for new anti-leukaemic agents has become an 
urgent need. 
There are several reports on remedial uses of E. longifolia to alleviate 
angiogenesis-related diseases (Kavitha et al., 2010) and there is even 
evidence that this plant is endowed with abundance of bioactive constituents, 
particularly the quassinoids, with significant anti-tumor and anti-angiogenic 
activities (Bhat and Karim, 2010; Kuo et al., 2004; Salamah et al., 2010). 
Several studies showed anti-proliferative activity on varying types of solid 
tumors, including lung cancer (Ueda et al., 2002; Wong et al., 2012), breast 
cancer (Tee et al., 2007), cervical carcinoma (Mahfudh and Pihie, 2008) and 
HepG2 (Zakaria et al., 2009). This has drawn attention toward hypothesizing 
that E. longifolia could contain potential anti-neoplastic activity against the 
blood cancer: leukaemia. 
The anti-neoplastic activity of Eurycoma longifolia against leukaemia 
disease has not been addressed yet. Additionally, studying the mechanism by 
which Eurycoma longifolia exerts its effect on leukaemic cells may lead 
researchers to explore new therapeutic targets. Also, the evaluation of the 
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combination effect of extracts from Eurycoma longifolia with imatinib may 
help reverse the resistance to or enhance the effects of imatinib. 
 
1.6 Hypothesis 
Root extract of E. longifolia (TAF273) has anti-neoplastic activity on leukaemia in 
vitro and in vivo. 
TAF273 has no toxicity in nude mice model.  
TAF273 induces apoptosis and cell cycle arrest in leukaemic cells. 
TAF273 enhances the activity of imatinib. 














1.7   Objectives of Study 
1.7.1 Main Objective 
   This study aimed to investigate the anti-neoplastic activity of E. longifolia extracts 
on blood cancer: leukaemia. 
1.7.2   Specific Objectives 
 To investigate the anti-neoplastic activity of standardized root extract of E. 
longifolia (TAF273) against leukaemia models, in vitro and in vivo. 
 To evaluate the toxicity of TAF273 extract in nude mice model. 
 To determine the mechanism of action of TAF273 extract on K-562 
leukaemia cells. 
 To evaluate the effects of the combination of TAF273 extract with a standard 
anti-leukaemia drug (imatinib) on K-562 cells. 









































2.1   Origin of Blood Cells  
   Blood is one of the most highly regenerative tissues in the human body and is 
composed of an assortment of cells suspended in plasma. Most blood cells that 
circulate throughout the body have a relative short lifespan, dying off while newly 
formed cells take their place via haematopoiesis. Approximately 1012 cells are 
produced daily in adult human bone marrow (Doulatov et al., 2012; Peixoto et al., 
2011) and this rate may be increased to 10 times or even more when the demand to 
blood production increases (Kaushansky, 2006; Ogawa, 1993). 
   Haematopoiesis (from ancient Greek: haima blood; poiesis to make) is the 
formation of blood cells in a living body. Haematopoiesis is a complex process 
involving the continuous generation of a spectrum of highly specialized, 
differentiated cell types (Orkin, 2000) as shown in Figure 2.1. The haematopoietic 
system consists of pluripotential stem cells (most primitive and self sustaining), 
progenitor cells (lineage restrictions and little or no self renewal capacity) and 
lineage-restricted, maturing cells (Lansdorp, 1995; McCulloch, 1983). 
The final products of the haemopoietic stem cell differentiation are the 
progenitors of all blood cell lineages, such as erythrocytes, neutrophils, eosinophils, 
basophils, monocytes, macrophages, B and T lymphocytes, natural killer cells and 
platelets (Kaushansky, 2006; McCulloch, 1983). 
    The level of blood cells is controlled by a number of cellular and humoral 
factors and adjusts rapidly according to requirement (Kaushansky, 2006; Ogawa, 
1989). For example, in response to microbial infection, an immediate release of 
mature neutrophils and an increased production of granulocytes and monocytes will 
take place until the infectious agents are cleared. Upon haemorrhage or acute 
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haemolysis, a rapid release of bone marrow reticulocytes along with an increase in 
red cell production will occur to adequately compensate for the loss (Takizawa et al., 
2012).
 
Figure 2.1 Schematic diagram of haematopoiesis. 
Haematopoiesis has a tree-like structure with the haematopoietic stem cells at the root of the 
process. Each cell division gives rise to progeny cells that can retain the properties of their 
parent cell (self-renewal) or differentiate, ‘‘moving down’’ the haematopoietic tree. As the 
progeny move further away from the HSC, their pluripotent ability is increasingly restricted 
(CMP: common myeloid progenitor; CLP: common lymphoid progenitor; BFU-E: erythroid 
burst forming unit; CFU-GM: granulocyte–macrophage colony forming unit). PLT; platelets; 
RBC: red blood cells; Neut: neutrophil; Eo: eosinophil; Baso: Basophil; Mono: monocyte; B: 




2.2   Haemopoietic Stem Cell Disorders 
2.2.1   Classification 
  The haemopoietic stem cell disorders are classified into two principal 
pathogenetic disorders: aplasia (stem cell failure) and clonal haemopathies (injury to 
a single cell within the haemopoietic stem cell pool) (Lichtman, 1995a). 
Aplasia comprises a heterogeneous group of diseases characterized by peripheral 
blood pancytopenia with a hypocellular bone marrow and remarkable reduction of 
blast cells (Lichtman, 1995a; Raghavachar et al., 1995). 
 Clonal haemopathies or clonal haematopoiesis is a group of haematopoietic 
disorders including the pre-leukaemias and myeloproliferative neoplasms (MPN). 
These disorders are characterized by an overwhelming production and excessive 
accumulation of granulocytes, erythrocytes, and platelets in the bone marrow, 
peripheral blood, and tissues (Wadleigh and Tefferi, 2010; Vardiman et al., 2009). 
Chronic MPNs include chronic myelogenous leukaemia (CML), chronic 
monocytic leukaemia (CMML), chronic neutrophilic leukaemia, idiopathic 
myelofibrosis, polycythemia vera and primary thrombocythemia (Cervantes et al., 
2005; Lichtman, 1995a; Lichtman, 2005; Vardiman et al., 2009). 
   The development of AML occurs when MPN reaches its terminal stage. AML 
develops in 75% of patients with CML and in 15% of patients with primary 




2.2.2   Leukaemia 
Leukaemia is characterized by an uncontrolled proliferation of one cell line or a 
stem cell common to several cell lines. Leukaemia is one of the most common forms 
of cancer, especially in children (Lichtman, 1995a; Reya et al., 2001). 
 Leukaemias are classified into two major groups: (i) chronic, in which the onset 
is insidious and is usually less aggressive (Geary et al., 1975); (ii) acute, which is 
characterized by a rapid onset, aggressiveness and poor differentiation with many 
blasts. AML is more common in adults, while ALL is more common in children 
(Hoelzer et al., 2002; Muntean and Hess, 2012; Xie et al., 2003). 
Chronic leukaemias represent a group of diseases that include both CML and CLL 
malignancies (Cotta and Bueso-Ramos, 2007; Bergsagel, 1967).  
2.2.2.1   Chronic Myeloid Leukaemia (CML) 
Chronic myeloid leukaemia (CML) is a clonal disorder involving a pluripotent 
haematopoietic stem cell (Morrison, 1994). The disease was described in 1845 by 
three pathologists, Craigie, Bennett, and Virchow, working independently (Steinberg, 
2007; Wong and Witte, 2004). CML is a disease commonly associated with the 
elderly with a slight male predominance. The average age of patients with CML at 
diagnosis is 45 to 55 years (Epstein et al., 1999; Morrison, 1994).  
   The characteristic presenting feature of CML is an elevated white blood cell 
count (50 000 -300 000 per ml) with a high percentage of mature neutrophils with 
metamyelocytes and myelocytes and few blasts (Radich, 2007; Wertheim et al., 
2002). Basophils and eosinophils are also frequently present. Some patients exhibit 
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splenomegaly; however, nearly 40% are asymptomatic. Bone marrow biopsy reveals 
a marked myeloid hyperplasia (Radich, 2007; Wertheim et al., 2002). 
Clinically, CML is classified into three phases: the chronic phase (CP), the 
accelerated phase (AP) and the blast crisis (BC) (Melo and Barnes, 2007; Rizzieri 
and Moore, 2012). Patients who suffer from CML may remain in CP for up to 5 
years and are generally asymptomatic (Melo and Barnes, 2007; Rizzieri and Moore, 
2012). The accelerated phase is characterized by genetic instability and constitute up 
to 10–15% blasts, 20–30% blasts with promyelocytes, over 20% basophils, and a 
platelet count of less than 100 x 109/L (Rizzieri and Moore, 2012). The AP is more 
aggressive than CP and generally lasts between 4–6 months. The blast crisis phase is 
by far the most tenacious of the phases of CML, and only has a median survival rate 
of 4–6 months (Melo and Barnes, 2007; Saglio et al., 2010).  
Patients in the BC phase could exhibit several symptoms, including fever, cold 
sweats, fatigue, and anorexia. Furthermore, patients may experience splenomegaly, 
and may complain of bone pain (which could signify an infection) (Morrison, 1994; 
Steinberg, 2007; Wong and Witte, 2004).  Splenomegaly is reported in 40–60%, of 
cases and hepatomegaly in 10–20% (Garcia-Manero et al., 2003). 
2.2.2.1.1   Molecular basis of CML  
2.2.2.1.1.1   Philadelphia Chromosome 
   The Ph chromosome is the hallmark of CML and was discovered in 1960 by 
Nowell and Hungerford (Steinberg, 2007). It is found in more than 95% of CML 
patients, in 5% of children, and in 10–20% of adults with ALL (Clark et al., 1989; 
Epstein et al., 1999; Laurent et al., 2001; Steinberg, 2007). 
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As shown in Figure 2.2, one can see that the Ph chromosome is the product of a 
reciprocal translocation, located between the long arms of chromosomes 9 and 22; 
t(9;22)(q34;q11). This translocation adds a 3' segment of the ABL gene found in 
chromosome 9q34 to the 5' section of the BCR gene in chromosome 22q11, thus 
producing a hybrid BCR/ABL gene—which in turn is transcribed into a chimeric 
BCR/ABL mRNA (De Braekeleer et al., 2011; Deininger et al., 2000; Epstein et al., 
1999).   
 
 
Figure 2.2  Schematic illustration of t(9;22)(q34;q11), break points and  
ABL/BCR chimeric proteins in CML 




   The ABL or ABL1 (v-abl Abelson murine leukaemia viral oncogenes homolog 
1) proto-oncogene encodes a non-receptor tyrosine kinase with a molecular mass of 
145 kd (p145ABL). ABL protein is ubiquitously expressed and is involved in signal 
transduction via integrins, in cell cycle regulation and in response to DNA damage. 
The ABL gene spans 230 kb and is located at band 9q34. It includes the 5´ 
alternative first exons 1b and 1a and 10 common exons numbered from 2 to 11. ABL 
protein has 2 isoforms arising from an alternative splicing of the first exon (De 
Braekeleer et al., 2011; Deininger et al., 2000; Epstein et al., 1999). 
The breakpoint cluster region (BCR) spans 130 kb and contains 23 exons 
(Laurent et al., 2001). The BCR gene encodes two major proteins, named Mr160 kd 
and Mr 130. Other BCR proteins, such as Mr 190kd, Mr 155 kd, Mr 135kd, Mr 
125kd, and Mr 108kd are also described (Laurent et al., 2001). The BCR proteins are 
signalling proteins and are reported to be involved in two major signalling 
mechanisms, including phosphorylation and the GTP-binding protein (Laurent et al., 
2001; Ren, 2005). 
   The major breakpoint cluster region (M-bcr) of the BCR gene on chromosome 
22 extends over 5.8 kb and is located between exon 12 and 16 (originally referred to 
as exons b1-b5) (Deininger et al., 2000). Two fusion transcripts, e13a2 and e14a2 
(b2a2 and b3a2, respectively) are generated and both translate into a chimeric protein 
of 210 kd, named p210BCR/ABL (Deininger et al., 2000; Laurent et al., 2001; Ren, 
2005). In 95% of the BCR/ABL positive CML, the leukaemic cells contain either the 
b2a2 transcript or the b3a2 transcript, where both fusion products are present in 
about 5% of the cases (Melo, 1996). Those who exhibit b2a2 and b3a2 transcripts 
have a very similar set of symptoms, as well as response to treatment and prognosis. 
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But there is one difference: patients with b3a2 transcripts have a higher platelet count 
(Junia, 1996).  
   The minor breakpoint cluster region (m-bcr) results from the fusion of e1 exon 
of the BCR gene with the a2 exon of the ABL gene producing fusion  transcript 
called e1a2, which encodes for a 190 kd protein, p190BCR/ABL (Deininger et al., 
2000; Laurent et al., 2001) (Figure 2.2).  
P190BCR/ABL is rare in CML and is mainly found in children and adults with Ph 
chromosome positive ALL (Deininger et al., 2000; Verma et al., 2009).  
Another unique breakpoint cluster region (µ-bcr) was determined downstream 
of exon 19, producing a 230-kd fusion protein (P230BCR-ABL). It is resulted from the 
fusion between exon 19 of the BCR gene and exon 2 of ABL (e19a2). This 
breakpoint is associated with the rare Ph chromosome positive chronic neutrophilic 
leukaemia and rarely occurs in CML (Deininger et al., 2000; Verma et al., 2009). 
2.2.2.1.1.2   The BCR/ABL Oncoprotein 
The leukaemogenic potential of p210BCR/ABL results from the constitutive 
activation of tyrosine kinase of the ABL protein (Epstein et al., 1999). ABL proteins 
are non-receptor tyrosine kinases, and play a significant part in both regulating cell 
growth and acting as a signal transduction (Wang, 1993). Isoform 1a and isoform 1b 
have been reported as two isoforms of ABL.  
   The high expression of isoform 1b in early haematopoietic progenitor cells is 
associated with myristoylation at the second glycine residue at the N-terminal 
(Jackson and Baltimore, 1989). A defect in myristoylation in ABL markedly 
enhances its tyrosine kinase activity (Hantschel et al., 2003). 
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2.2.2.1.1.3   Regulatory Function of SRC Homology Domains 
  There are three SRC homology domains downstream from the myristoylation 
site (located at the N-terminal portion of ABL); SRC homology domains 1 (SH1), 
SRC homology domains 2 (SH2) and SRC homology domains 3 (SH3). The SH2 
and SH3 regulate the tyrosine kinase function of ABL in a negative way, while SH1 
harbors its tyrosine kinase activity. By removing the SH3 or mutation in SH3 will 
increase ABL tyrosine kinase activity (Ben-Neriah et al., 1986; Franz et al., 1989). 
Any defects that may be located in SH2’s structure would lessen phosphotyrosine 
binding and thus decrease the transforming abilities of ABL (Faderl et al., 1999).  
   The ungoverned BCR/ABL tyrosine kinase activity results from the combination 
of various BCR sequences. It was found that the coil-coiled N-terminal motif of BCR 
promotes dimerization and enhances BCR/ABL tyrosine kinase activity. This motif 
also enables the binding of F-actin to ABL (Goldman and Melo, 2003; McWhirter et 
al., 1993). The BCR activates via its serine-threonine kinase domain—the signalling 
pathways mediated by BCR/ABL tyrosine kinase (Muslin et al., 1996) (Figures 2.3 









Figure 2.3  Functional domains in p160BCR, p145ABL and p210BCR-ABL. 
Important functional domains of the BCR and ABL gene products as well as different 
fusion-protein products are shown (p190BCR/ABL, p210BCR/ABL and p230BCR/ABL). Breakpoints 
are indicated by arrowheads. N: N-terminal amino acid sequence, C: C-terminal amino acid 
sequence, Ser-thr: serine-threonine, GDP: guanosine diphosphate, GTP: guanosine 
triphosphate, GEF: GDP-GTP exchange factor, DBL: diffuse B-cell lymphoma oncogene, 
RAC: a RAS-like GTPase, GAP: guanosine triphosphatase-activating function protein, and 





Figure 2.4  Physiologic regulation by the normal ABL protein and deregulation 
by BCR/ABL of key cellular processes. 
 (Goldman and Melo, 2003)  
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The BCR/ABL protein interacts with various proteins resulting in transduction 
of the oncogenic signals responsible for several cellular effects such as the repression 
or activation of gene transcription, the degradation of inhibitory proteins, 
cytoskeletal organization, and mitochondrial processing of apoptotic responses (Dai 
et al., 2001). 
   As of yet, the key pathways implicated include RAS, MYC, mitogen-activated 
protein (MAP) kinases, phosphatidylinositol 3-kinase (PI3K), signal transducers and 
activators of transcription (STAT). Numerous domains in BCR/ABL bind to various 
adapter proteins, such as CRK-like protein (CRKL), CRK, growth factor receptor-
bound protein 2 (GRB2), DOK, casitas B-lineage lymphoma SRC homology 2-
containing protein (SHC), and pro-oncogene proteins (CBL) (Goldman and Melo, 
2003; Puil et al., 1994). See Figure 2.5 below. 
 
 
